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Abstract
Background: Evidence is limited on ethnic differences in as-
sociations between kidney function markers and mortality 
or cardiovascular disease (CVD). Methods: Baseline cross-
sectional analysis and longitudinal follow-up study of a UK 
population-based cohort of 1,116 Europeans and 1,104 
South Asians of predominantly Indian descent, age 52 ± 
7 years at baseline (1988–1991). Kidney function was esti-
mated using Cystatin C and creatinine-based chronic kidney 
disease (CKD) Epidemiology Collaboration estimated glo-
merular filtration rate (eGFR) equations, and urinary albu-
min-creatinine ratio (ACR). Mortality was captured at 27 
years, and incident CVD at 22 years, from death certification, 
medical records and participant report. Longitudinal asso-
ciations between eGFR/ACR and mortality/incident CVD 
were examined using Cox models. Results: eGFRcys was low-
er and ACR higher in South Asians than Europeans. eGFRcys 
and  eGFRcreat were more strongly associated with outcomes 
in Europeans than South Asians. Conversely, associations be-
tween ACR and outcomes were greater in South Asians than 
Europeans, for example, for CVD mortality: HRs (95% CI) ad-
justed for CVD risk factors and ACR/eGFRcys as appropriate, p 
for ethnicity interaction: eGFRcys: Europeans: 0.76 (0.62–
0.92), South Asians: 0.92 (0.78–1.07), p = 0.05, eGFRcreat: Eu-
ropeans 0.81 (0.67–0.99), South Asians 1.18 (0.97–1.41), p = 
0.002, ACR:  Europeans: 1.24 (1.08–1.42), South Asians: 1.39 
(1.25–1.57), p = 0.23. Addition of all CKD measures to a stan-
dard CVD risk factor model modestly improved prediction 
capability in  Europeans; in South Asians only ACR contrib-
uted to improvement. Conclusions: Strong associations be-
tween ACR and outcomes in South Asians of predominantly 
Indian origin, and null associations for eGFRcys and eGFRcreat, 
suggest that ACR may have greater utility in CVD risk predic-
tion in South Asians. Further work is needed to validate these 
 findings. © 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Chronic kidney disease (CKD), an established risk fac-
tor for all-cause mortality and cardiovascular disease 
(CVD) [1, 2], has an adult prevalence of 5% [3]. People of 
South Asian ancestry (from the Indian subcontinent) 
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constitute the largest UK ethnic minority group [4] and 
the fastest growing migrant group in the USA [5]. Most 
studies report similar estimated glomerular filtration rate 
(eGFR) levels in Europeans and South Asians [6–10], de-
spite the striking surfeit of CVD and end stage kidney 
disease in the latter group [11–14]. 
Data on longitudinal associations between CKD and 
mortality or CVD in South Asians are limited and contra-
dictory. To our knowledge, only 2 studies have reported 
South Asian ethnicity-specific associations between 
eGFR, albuminuria and mortality and/or CVD; one 
found no ethnic differences [8], while an earlier analysis 
in the Southall and Brent Revisited (SABRE) study de-
scribed stronger associations in South Asians than 
 Europeans for albuminuria; however data on eGFR were 
not reported and event numbers at that stage were rela-
tively low [14]. For the sole study reporting on eGFR, use 
of creatinine-based eGFR estimating equations may be 
biased [8], given creatinine is related to diet and muscle 
mass, both of which often vary considerably between 
South Asian and European populations [15, 16]. There-
fore eGFR equations based on Cystatin C [17] are consid-
ered preferable for use in non-white ethnic groups [18], 
but to our knowledge, no study has examined how cys-
tatin C-based eGFR relates to mortality or CVD out-
comes in South Asians.
Using data from a UK community-based cohort of 
 European and South Asian origin, our objectives were to 
study ethnic differences in (a) mid-life distributions of 
CKD markers and (b) longitudinal associations between 
CKD markers and 26-year mortality and 20-year CVD 
morbidity. There were insufficient end stage renal disease 
events for analysis.
Materials and Methods
The SABRE study is a multi-ethnic cohort study; details are 
published elsewhere [19]. In brief, participants aged 40–69 years at 
baseline (1988–1991) were randomly selected from primary care 
physician lists and workplaces in north-west London. South Asian 
participants were first-generation migrants originating from the 
Indian subcontinent and were recruited in Southall only.  European 
participants (largely UK-born) were recruited from both Southall 
and Brent. Stored blood samples were available only for partici-
pants recruited in Southall. Participants were followed for death, 
hospitalization, and primary care consultations from baseline to 
2015 (mortality) or 2011 (morbidity). We report findings from the 
subset of 1,116 European and 1,104 South Asian men and women 
who had baseline stored blood samples and urinary albumin-cre-
atinine ratio (ACR; Fig. 1). 
At baseline, participants attended clinic for a series of measure-
ments and completed a health and lifestyle questionnaire. This 
study uses measurements from baseline only. Creatinine and cys-
tatin C were measured in stored serum samples by an automated 
clinically validated platform (c311, Roche Diagnostics, Burgess 
Hill, UK) using the manufacturer’s calibrators and quality control 
material. Coefficient of variation of the serum assays was < 3.5%. 
Renal function was quantified by (i) CKD Epidemiology Collabo-
ration (CKD-EPI) eGFR estimating equations based on serum cys-
tatin C (eGFRcys, online suppl. Table S1; for all online suppl. mate-
rial, see www.karger.com/doi/10.1159/000503873) [17], as these 
may give more accurate results in people of non-European ethnic-
ity [18, 20], are less influenced by dietary patterns and differences 
in muscle mass than creatinine-based equations [21], and have a 
Europeans
(n = 1,761)
South Asians
(n = 1,761)
Baseline creatinine, cystatin
C and ACR available
(n = 1,116)
Baseline creatinine, cystatin
C and ACR available
(n = 1,104)
Follow-up
mortality data
available
(n = 978) 87%
Follow-up
mortality data
available
(n = 983) 90%
Follow-up
data for CVD
available
(n = 892) 88%
Follow-up
data for CVD
available
(n = 912) 90%
No baseline
CVD
(n = 1,013)
No baseline
CVD
(n = 1,012)
Fig. 1. Follow-up of the SABRE cohort, 
1988–2011. ACR, albumin-creatinine ra-
tio; CVD, cardiovascular disease.
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higher specificity for disease outcomes than creatinine-based mea-
sures [22], (ii) eGFR from CKD-EPI-creatinine equations 
 (eGFRcreat, online suppl. Table S1) [17] and (iii) ACR. We also used 
eGFR from the Modification of Diet in Renal Disease (MDRD) 
study equation (eGFRMDRD, online suppl. Table S1) in sensitivity 
analyses [23]. Urine ACR was measured at baseline using a highly 
sensitive immunoturbidimetric method [24] with goat anti-hu-
man albumin antisera (Sanofi Diagnostics, Pasteur, Chaska, MN, 
USA) and human serum albumin standards (ORHA 20/21 grade 
HAS; Behring Diagnostics, Hoechst, UK). Timed overnight urine 
collections were also performed in a subset of 915 Europeans and 
862 South Asians to enable calculation of albumin excretion rate 
(AER). Urine was tested to identify urinary tract infection; par-
ticipants with positive test results were asked to provide repeat 
samples. Microalbuminuria was defined as an ACR of 3–30 mg/
mmol. Physician diagnosis or World Health Organization 1999 
criteria for fasting and oral glucose tolerance test blood glucose 
measurements defined diabetes mellitus [25]. Antihypertensive 
use was ascertained by receipt of drugs in one of the following 
classes: ACE inhibitors, beta-blockers, CCBs, thiazides and other 
diuretics, reflecting contemporaneous use.
Deaths up to 2015 were flagged by the Office for National Sta-
tistics, and cause of death obtained from death certification (see 
below). Incident CVD was defined as coronary heart disease 
(CHD) and/or stroke up to 2011, from the following sources:
(1) From death certification (provided by NHS Digital on be-
half of the Office for National Statistics). Cause of death included 
any of the following for CHD: angina, myocardial infarction or its 
sequelae, or atherosclerotic heart disease using International Clas-
sification of Disease-Ninth Edition (ICD-9) codes 410 through 415 
or ICD-Tenth Edition (ICD-10) codes I200 through I259. For 
stroke, cause of death included ICD-9 codes 430 through 439 or 
ICD-10 codes I600 through I698.
(2) Primary care data were reviewed independently by 2 senior 
physicians blinded to participant ethnicity and identity. A CHD 
event was identified if both physicians agreed on definite or prob-
able diagnosis of myocardial infarction or acute coronary syn-
drome, according to pre-determined criteria used in the Anglo-
Scandinavian Cardiac Outcomes Trial [26], based on symptoms, 
cardiac enzymes, electrocardiography findings, and hospital dis-
charge diagnosis. Adjudication by a third physician was conduct-
ed if required. Coronary interventions (coronary artery bypass 
graft, angioplasty, stenting) were included as incident CHD 
events, as was angina confirmed on exercise testing. For stroke, 
primary care data were reviewed in a similar manner to CHD, 
with definite or probable diagnosis of stroke made according to 
pre-determined criteria based on symptoms, duration of symp-
toms, and magnetic resonance imaging or computed tomography 
imaging.
(3) Hospital Episode Statistics (provided by NHS Digital [for-
merly the Health and Social Care Information Centre]), using the 
following diagnostic codes for CHD: ICD-9: 410–415, ICD-10: 
I200–I259, and/or procedures pertaining to coronary revascular-
ization interventions or rehabilitation for ischemic heart disease, 
codes: K401-K469, K491-K504, K751-K759, U541 and the follow-
ing for stroke: (ICD-9: 430–439, ICD-10: I600–I698).
(4) Participant report of physician-diagnosed stroke and dura-
tion of symptoms in excess of 24 h.
CHD or stroke that occurred before baseline was identified 
from participant report (at baseline) of physician-diagnosed dis-
ease (or presence of major Q waves on baseline electrocardiogra-
phy for CHD).
All participants gave written informed consent. Approval for 
the baseline study was obtained from Ealing, Hounslow and Spelt-
horne, Parkside and University College London research Ethics 
Committees, and at follow-up from Fulham Local Research Ethics 
Committee (reference: 07/HO712/109).
Statistical Analysis
Baseline characteristics were compared by ethnicity and fol-
low-up status; logistic and linear regression models determined 
age- and sex-adjusted differences. Classification of CKD stage by 
either eGFRcys or eGFRcreat was compared, and cross-tabulated 
with ACR stages for each ethnic group [20]. ACR rather than AER 
was used in analyses to maximize power and comparability with 
other studies. For both Europeans and South Asians, longitudinal 
associations between standardized eGFRcys, eGFRcreat or ACR 
(log-transformed) and the following outcomes were studied: all-
cause mortality, CVD (CHD + stroke) mortality and incident CVD 
(non-fatal + fatal). Associations were initially adjusted for age and 
sex (model 1), followed by additional adjustment for ACR  (eGFRcys 
and eGFRcreat models) or eGFRcys (ACR models), (model 2), fol-
lowed by additional adjustment for CVD risk factors (smoking, 
systolic blood pressure, diabetes, fasting glucose, total/HDL-cho-
lesterol ratio, and BMI [plus baseline CVD for CVD mortality]), 
(model 3). Additionally, we inspected eGFR/ACR × ethnicity and 
eGFR × ACR interaction terms for each outcome. Cox propor-
tional hazards models were used – the proportional hazards as-
sumption was verified using a formal test of Schoenfeld residuals 
and by inspection of plots of outcome risk by tertile of CKD mark-
er in each ethnic group. Linearity of associations was checked us-
ing the likelihood ratio test, comparing tertiles of exposure versus 
the linear term. Sub-group analyses were performed by baseline 
diabetes status. Sensitivity analyses substituted eGFRMDRD for 
 eGFRcys or eGFRcreat (by CKD-EPI equations), AER for ACR, 
HbA1c for fasting glucose, and diabetes development as a time-
varying covariate (no diabetes vs. diagnosis after 2009 vs. diagnosis 
 1999–2008 vs. diagnosis 1988–2008 vs. baseline diabetes). 
Finally, we contrasted the predictive power of eGFRcys, 
 eGFRcreat, and ACR in turn, for each outcome and in both ethnic 
groups. We observed the change in the Harrell’s C statistic on ad-
dition of each CKD marker to an initial model containing age, sex, 
smoking, systolic blood pressure, diabetes, fasting glucose, total/ 
HDL-cholesterol ratio, and BMI (plus baseline CVD for CVD 
mortality). Analyses were conducted in Stata version 14.2.
Results
A total of 1,116 Europeans and 1,104 South Asians of 
predominantly Indian heritage had baseline data avail-
able on cystatin C, creatinine, and ACR; of these, 976 and 
982 respectively had follow-up mortality data, and slight-
ly fewer follow-up cardiovascular morbidity data avail-
able (Fig.  1). There were no consistent differences in 
baseline characteristics by follow-up status (online suppl. 
Table S2). All-cause mortality rates were lower in South 
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Asians than Europeans (298/983 [30%] vs. 385/978 
[39%] deaths, 13.5 [16.4–20.1] vs. 18.1 [16.4–20.1] per 
1,000 person years at risk [PYAR] respectively, age- and 
sex-adjusted p = 0.22), though South Asians had more 
CVD-related deaths (165/983 [17%] vs. 134/978 [14%], 
7.5 [6.4–8.7] vs. 6.3 [5.3–7.5] per 1000 PYAR, p < 0.001) 
and incident CVD (377/912 [41%] vs. 283/892 [32%] 
events, 25.2 [22.8–27.9] vs. 18.5 [16.4–20.7] per 1000 
PYAR, p < 0.001) than Europeans (Fig. 2).
Cross-Sectional Analyses
South Asians had more adverse levels of cystatin C, 
eGFRcys, and ACR than Europeans at baseline, and sim-
ilar creatinine and eGFRcreat (Table 1). Further, South 
Asians had worse CVD risk factor profiles than 
 Europeans (bar smoking rates, which were greater in 
Europeans than South Asians), but there were no ethnic 
differences in baseline CVD prevalence. No partici-
pants were receiving lipid lowering medications at 
baseline. Similar proportions of Europeans and South 
Asians had albuminuric CKD (11% of those with 
 eGFRcys < 60 mL/min/1.73 m2 in the former, and 8% in 
the latter, p = 0.67).
Our cross-tabulation of CKD stages by eGFRcys or 
 eGFRcreat showed that agreement was similar regardless 
of ethnicity (68.4% for Europeans vs. 67.8% for South 
Asians, p = 0.61, weighted kappa = 0.41 for both, online 
suppl. Table S3). However, for participants who were dis-
cordantly classified, more South Asians than Europeans 
were designated to a more adverse CKD stage when 
 eGFRcys, as opposed to eGFRcreat, was used (19 vs. 9%, 
p < 0.001, online suppl. Fig. S1).
Longitudinal Analyses
In age- and sex-adjusted models, eGFR was inversely 
related to mortality and incident CVD in Europeans (Ta-
ble 2); associations generally persisted after further ad-
justment for ACR or CVD risk factors, and were similar 
for eGFRcys and eGFRcreat. However, for South Asians, as-
sociations were weaker (e.g., risk factor-adjusted associa-
tions between eGFRcys and CVD mortality: HRs [95% CI]; 
Europeans 0.76 [0.62–0.92] vs. South Asians 0.92 
 [0.78–1.09], ethnicity interaction p = 0.05), or absent 
when eGFRcreat was used in risk factor-adjusted models. 
In contrast, age- and sex-adjusted associations between 
ACR and outcomes were of at least similar or greater 
magnitude in South Asians than Europeans (e.g., for 
 eGFRcys– and risk factor-adjusted models of all-cause 
mortality: Europeans 1.16 [1.06–1.27] vs. South Asians 
1.26 [1.14–1.39], ethnic difference p = 0.04; Table 2). 
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Fig. 2. Cumulative hazards of mortality and morbidity by ethnicity: (a) all-cause mortality, (b) cardiovascular 
mortality and (c) incident CVD.
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There was no evidence against linearity of associations for 
any independent variable. Results were similar when peo-
ple with baseline diabetes were excluded, or for associa-
tions between eGFRMDRD, cystatin C or AER and out-
comes (online suppl. Table S4), or when substituting 
HbA1c for fasting glucose, or considering diabetes as a 
time-varying covariate (data not shown). There were no 
statistically significant interactions between eGFR and 
ACR for any outcome. 
We then assessed whether addition of any CKD mea-
sure improved a standard risk factor prediction model 
for all-cause and CVD mortality and incident CVD 
events (online suppl. Table S5). In Europeans, addition 
of eGFRcys (and to a lesser extent eGFRcreat) or ACR 
modestly increased Harrell’s C statistics for mortality 
and incident CVD. In contrast, for South Asians, in-
creases in the C-statistic were seen on addition of ACR 
to mortality models, but hardly at all on addition of 
 eGFRcys or eGFRcreat, and there were no improvements 
in predictive power for addition of any renal marker to 
incident CVD models. 
Discussion
We report the following novel findings: first, South 
Asians (of mostly Indian descent) had more adverse 
levels of eGFRcys than Europeans in this predominant-
ly  male sample of middle-aged individuals. Second, 
agreement between CKD classification by eGFRcys vs. 
eGFRcreat did not differ by ethnicity, though more South 
Asians than Europeans were re-classified to a more ad-
verse stage when eGFRcys was used. Third, eGFR ap-
peared more strongly related to all-cause and CVD 
mortality in  Europeans, whilst ACR was more strongly 
related to these outcomes in South Asians. Finally, ad-
Table 1. Baseline characteristics by ethnicity
Europeans South Asians p value
Number 1,116 1,104 –
Gender, male 934 (84) 881 (80) 0.03
Age, years 54±7 52±7 <0.001
Cystatin C, mg/L 0.67 (0.47–0.90) 0.77 (0.55–1.00) <0.001
eGFRcys, mL/min/1.73 m2 117±37 107±37 <0.001
eGFRcys ≤60 mL/min/1.73 m2 76 (7) 118 (11) <0.001
Creatinine, µmol/L 78 (66–90) 76 (63–89) 0.51
eGFRcreat, mL/min/1.73 m2 92±19 95±18 0.73
eGFRcreat ≤60 mL/min/1.73 m2 47 (4) 40 (3) 0.63
ACR, mg/mmol 0.51 (0.38–0.74) 0.54 (0.37–0.89) 0.001
Microalbuminuria (ACR 3–30 mg/mmol) 43 (4) 55 (5) 0.08
Albumin excretion rate, µg/min 3.5 (2.5–5.3) 3.4 (2.3–5.9) 0.14
Smoking: never/ex/current, % 31/30/39 80/11/9 <0.001
SBP, mm Hg 123±17 126±19 <0.001
On antihypertensive medication 155 (14) 175 (16) 0.005
ACE inhibitor use 6 (0.5) 25 (2) <0.001
Diabetes 57 (5) 227 (21) <0.001
On antidiabetic medication 23/57 (40) 110/227 (48) 0.17
HbA1c, mmol/mol 37 (35–40) 40 (37–45) <0.001
HbA1c, % 5.5 (5.3–5.8) 5.8 (5.6–6.3) <0.001
Fasting glucose, mmol/L 5.3 (5.0–5.6) 5.5 (5.1–6.1) <0.001
Total cholesterol: HDL cholesterol ratio 4.7 (3.8–5.8) 4.9 (4.1–6.0) <0.001
Triglycerides, mmol/L 1.4 (1.0–2.1) 1.7 (1.2–2.5) <0.001
WHR 0.92±0.09 0.97±0.08 <0.001
BMI, kg/m2 26.1±4.0 26.2±3.8 0.84
Baseline CVD 116 (10) 111 (10) 0.26
Data are n (%), unadjusted mean ± SD, or median (IQR), p value for ethnic difference adjusted for age and 
sex.
Includes all for whom baseline cystatin C, creatinine and ACR were available.
ACR, albumin-creatinine ratio; CVD, cardiovascular disease; IQR, interquartile range.
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Table 2. Longitudinal associations between baseline eGFR or ACR and mortality or incident CVD, by ethnicity
CKD measure Model Europeans South Asians p value#
All-cause mortality to 2015
eGFRcys 0 0.72 (0.65–0.80)*** 0.77 (0.68–0.87)*** 0.48
1 0.83 (0.75–0.92)** 0.91 (0.81–1.03) 0.20
2 0.84 (0.76–0.93)** 0.93 (0.82–1.05) 0.29
3 0.83 (0.74–0.93)** 0.90 (0.79–1.02) 0.31
eGFRcreat (1 SD increase) 0 0.74 (0.67–0.81)*** 0.79 (0.71–0.89)*** 0.29
1 0.91 (0.82–1.02) 1.06 (0.93–1.21) 0.04
2 0.92 (0.83–1.03) 1.07 (0.94–1.22) 0.10
3 0.92 (0.82–1.03) 1.05 (0.92–1.20) 0.11
ACR (1 SD increase) 0 1.28 (1.18–1.39)*** 1.39 (1.27–1.52)*** 0.18
1 1.21 (1.11–1.31)*** 1.40 (1.27–1.54)*** 0.009
2 1.19 (1.10–1.30)*** 1.40 (1.27–1.53)*** 0.008
3 1.16 (1.06–1.27)** 1.26 (1.14–1.39)*** 0.04
CVD mortality to 2015
eGFRcys (1 SD increase) 0 0.59 (0.49–0.71)*** 0.74 (0.63–0.87)*** 0.07
1 0.69 (0.58–0.83)*** 0.89 (0.76–1.04) 0.02
2 0.71 (0.59–0.85)*** 0.91 (0.78–1.07) 0.04
3 0.76 (0.62–0.92)** 0.92 (0.78–1.09) 0.05
eGFRcreat (1 SD increase) 0 0.62 (0.53–0.72)*** 0.82 (0.70–0.96)* 0.01
1 0.75 (0.63–0.91)** 1.13 (0.95–1.35) 0.001
2 0.78 (0.65–0.93)** 1.15 (0.96–1.37) 0.002
3 0.81 (0.67–0.99)* 1.18 (0.97–1.41) 0.002
ACR (1 SD increase) 0 1.39 (1.22–1.57)*** 1.51 (1.35–1.69)*** 0.32
1 1.28 (1.13–1.46)*** 1.52 (1.37–1.69)*** 0.05
2 1.25 (1.10–1.42)** 1.51 (1.36–1.69)*** 0.05
3 1.24 (1.08–1.42)** 1.39 (1.25–1.57)*** 0.23
Incident CVD (excludes those with baseline CVD) to 2011
eGFRcys (1 SD increase) 0 0.75 (0.66–0.84)*** 0.84 (0.75–0.94)** 0.18
1 0.81 (0.72–0.92)** 0.91 (0.81–1.01) 0.09
2 0.82 (0.72–0.93)** 0.91 (0.81–1.02) 0.12
3 0.87 (0.77–0.99)* 0.92 (0.82–1.03) 0.30
eGFRcreat (1 SD increase) 0 0.76 (0.68–0.85)*** 0.87 (0.78–0.97)* 0.09
1 0.86 (0.76–0.97)* 1.00 (0.89–1.13) 0.01
2 0.87 (0.76–0.98)* 1.00 (0.89–1.13) 0.02
3 0.92 (0.80–1.05) 1.02 (0.90–1.16) 0.03
ACR (1 SD increase) 0 1.19 (1.07–1.32)** 1.18 (1.07–1.30)** 0.96
1 1.14 (1.03–1.26)* 1.20 (1.09–1.33)*** 0.40
2 1.13 (1.02–1.24)* 1.20 (1.09–1.32)*** 0.36
3 1.08 (0.97–1.21) 1.08 (0.97–1.20) 0.78
ACR log-transformed.
Data are HR (95% CI), *** p < 0.001, ** p <0.01, * p < 0.05, # p = p value for ethnicity × CKD measure inter-
action term.
Model 0: unadjusted, model 1: age + sex, model 2: age + sex + ACR/eGFRcys, model 3: age + sex + ACR/ eGFRcys 
+ smoking + SBP + diabetes + fasting glucose + TC/HDL + BMI (+ baseline CVD for cardiovascular mortality).
Includes all for whom cystatin C, creatinine and ACR available.
ACR, albumin-creatinine ratio; CVD, cardiovascular disease; CKD, chronic kidney disease.
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dition of eGFR and ACR to standard CVD risk factor 
models improved the predictive power for mortality 
and CVD events in  Europeans, but only addition of 
ACR to mortality models gave any improvement for 
South Asians.
Our observation of lower eGFRcys and higher ACR in 
South Asians than Europeans is in keeping with the dis-
proportionate rates of end-stage renal failure experienced 
by UK South Asians, likely mediated by the much greater 
diabetes prevalence in the former group [6, 12, 13, 27]. 
Previous studies reporting eGFR comparisons in these 
groups have used the MDRD creatinine-based estimating 
equation [23] and found no ethnic differences in eGFR 
[6–10] although most, but not all [14], report higher lev-
els of albuminuria in South Asians with [7, 9, 28] and 
without diabetes [6, 8, 10, 29]. We also found no ethnic 
differences when creatinine-based eGFR measures were 
compared.
In our comparison of the agreement between CKD 
stage by eGFRcys and eGFRcreat, we found no ethnic dif-
ference in the overall agreement, though South Asians 
were more likely to be re-classified to a more adverse 
CKD stage by eGFRcys, in keeping with the slightly more 
adverse longitudinal associations we found between 
 eGFRcys than eGFRcreat and outcomes. 
We believe our study to be the first to compare South 
Asians and Europeans with regard to eGFRcys levels and 
their associations with cardiometabolic risk factors and 
CVD outcomes.
Lower eGFR, however defined, was more strongly 
associated with mortality and incident CVD in Europe-
ans than South Asians. The only other study (of 
 Canadian primary care records) addressing this com-
parison showed no ethnic differences in associations 
between eGFR and mortality/CVD outcomes between 
South Asians and  Europeans [8], though eGFRMDRD 
was used, the study population was younger than ours 
and bias may have been introduced by designating eth-
nicity on surname alone. ACR was more strongly asso-
ciated with longitudinal (mortality/CVD) outcomes in 
South Asians than  Europeans. Furthermore, in predic-
tion models of mortality and CVD outcomes, both 
eGFR and ACR led to small improvements in predictive 
ability in Europeans, but only ACR increased the pre-
dictive power for South Asians, and only for mortality 
models. 
CKD-EPI equations have not been validated in UK/US 
South Asian migrant populations [30], therefore a pos-
sible explanation for the weaker associations seen be-
tween eGFR and outcomes in South Asians compared to 
Europeans is poor correlation between eGFR and mGFR 
in this population. However, recent data from India sug-
gest a good correlation between CKD-EPI eGFRcys – al-
beit not CKD-EPI eGFRcreat – and mGFR [31], corrobo-
rating findings in South Asian migrant groups elsewhere 
[32–34]. It has been argued previously that cystatin C-
based equations should be more accurate than creatinine-
based ones in ethnic minority groups [18, 20, 32, 33], 
since cystatin C is considered to be independent of mus-
cle mass and dietary protein intake, which may differ by 
ethnic group [15, 16].
Another potential explanation of our findings is that 
eGFR and ACR represent complementary manifestations 
of kidney damage [35]; eGFR may be a superior indicator 
of cardiometabolic health in Europeans, and ACR in 
South Asians. The role of eGFR in the pathogenesis of 
CVD is unclear; a recent Mendelian randomization study 
was unable to establish conclusively whether GFR had a 
direct effect on CHD [36]. Some authors argue that de-
cline in eGFR merely represents duration of exposure to 
traditional CVD risk factors, that is, it is a “parallel” risk 
factor [37]. In contrast, it has been suggested that albu-
minuria is an early marker of more aggressive damage to 
susceptible circulations, not just of glomerular damage 
[38], and that albuminuria and CVD are linked by a com-
mon pathway of microvascular and endothelial dysfunc-
tion [39–41].
Mechanistic pathways linking CKD markers to mor-
tality/CVD outcomes may differ by biomarker and eth-
nicity, such that in Europeans (with their much lower 
prevalence of diabetes and hyperglycemia) the predomi-
nant pathway may be due to aging, of which eGFR may 
be the superior indicator. In South Asians, on the con-
trary, baseline measures of glycemia were more strongly 
associated with ACR, suggesting a predominant pathway 
involving glycemia and microcirculatory/endothelial 
dysfunction, of which ACR is the superior indicator [42]. 
The etiology of these ethnic differences in CKD pathways 
may relate to genetic, epigenetic or other influences act-
ing over the life course [41]. 
Strengths and Limitations
This longitudinal study is unique in comparing asso-
ciations between eGFRcys or ACR and mortality or inci-
dent CVD in Europeans and South Asians, with excellent 
follow-up rates and adequate power to show ethnic differ-
ences. By studying data from ethnic groups with different 
levels of CVD risk factors, we have provided fresh mecha-
nistic insights into pathways linking CKD and CVD. A key 
strength was the use of cystatin C for eGFR equations, a 
Eastwood/Chaturvedi/Sattar/Welsh/
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filtration marker generally considered to be independent 
of body composition and diet [21]. Whilst a single CKD 
measurement may not adequately represent lifetime ex-
posure, imprecision in the measurement of exposures is 
unlikely to obscure ethnic differences. However, data were 
not available for rates of decline of CKD markers, which 
may be more rapid in South Asians than Europeans [6, 9], 
and is an important predictor of disease outcomes [43]. 
Equally, no data were available on the duration or etiology 
of kidney injury at baseline, and there were too few renal 
events for analyses at follow-up. Potential confounders 
may have varied over time, especially with regards to life-
style, weight change, dietary composition, lipid levels, and 
use of statins, anti-hypertensives, and anti-diabetic medi-
cation. Allowing for diabetes as a time-varying covariate, 
however, did not alter results and we have shown than 
baseline antihypertensive use was greater in South Asians, 
but unfortunately do not have adequate data to further ex-
plore this conjecture. Finally, the UK South Asian popula-
tion in our study was of predominantly Indian origin, thus 
caution should be exercised in applying findings to other 
South Asian sub-groups, who may differ in their diet, risk 
factors, and body habitus.
In this longitudinal comparison of UK ethnic groups, 
we have shown that eGFRcys was lower in South Asians 
than Europeans, while eGFRcreat was similar in the 2 
ethnic groups. In contrast, ACR levels were higher and 
more strongly related to CVD outcomes in South 
Asians than Europeans. Both markers improved the 
prediction of outcomes for Europeans, but for South 
Asians only ACR enhanced predictive capability of 
models. These findings suggest mechanistic differences 
in how CKD markers relate to mortality and CVD in 
different ethnic groups. If corroborated, our results in-
dicate that ACR may have greater utility compared 
with eGFR in the prediction of CVD risk and mortal-
ity in South Asians. 
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